Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company focused on advanced wound care and surgical biologics products that completed its de-SPAC merger with Avista Healthcare Public Acquisition Corp, sponsored by Avista Capital Partners, in December 2018. The blank-check vehicle originally listed in 2017 targeting the healthcare sector, and the combined company has traded publicly on Nasdaq since the transaction closed. Organogenesis filed this Form 8-K current report with the SEC on December 30, 2021, continuing its standard public-company disclosure obligations in the wound care and regenerative medicine space. For full filing history, deal data, and sponsor analytics on Organogenesis and hundreds of other SPAC transactions, sign up for SpacDesk at spacdesk.com.